NetraMark Holdings Inc., a Toronto-based company specializing in AI technology for the pharmaceutical industry, celebrated its new listing on the Toronto Stock Exchange (TSX). Their flagship AI product, NetraAI, analyzes complex clinical trial data to identify patient subgroups and treatment signals that traditional methods miss, helping to optimize trial design and decision-making. This listing marks a significant step for NetraMark as it aims to support better clinical development and precision medicine. The company’s leadership, alongside TSX officials, officially opened the market to mark the occasion.
Warner Bros. Discovery's stock fell 4% following a court decision to pause the $110 billion merger deal between Paramount and Skydance. The judge's intervention raises uncertainty about the future of this major entertainment industry consolidation. I...
AT&T's baby bonds currently offer a 6.7% yield and trade at a 20% discount to par value due to elevated interest rates. The company reported solid Q2 results with $31.6 billion in revenue and $5.04 billion in net profit, ensuring strong coverage for ...
Michael Saylor shared a bitcoin acquisition chart for Strategy Inc., which holds 843,775 BTC worth about $54.36 billion and maintains a $3.225 billion cash reserve. The company recently raised $263.5 million by selling stock but did not buy more bitc...
Arthur Hayes, co-founder of BitMEX, purchased 1,290 ETH worth about $2.5 million, adding to growing interest in Ethereum as it consolidates below the critical $1,900 resistance level. Analysts are watching closely to see if ETH can break above $1,900...
Betterware received a reiterated 'Buy' rating with a two-year price target of $24.70–$25.60, implying about 48% upside plus a 7% dividend yield. The integration of Tupperware has significantly improved the company's earnings, increasing pro forma EPS...
